{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T15:10:59Z","timestamp":1781277059887,"version":"3.54.1"},"update-to":[{"DOI":"10.1002\/14651858.cd004756.pub3","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2017,7,20]],"date-time":"2017-07-20T00:00:00Z","timestamp":1500508800000}}],"reference-count":127,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2017,7,20]],"date-time":"2017-07-20T00:00:00Z","timestamp":1500508800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"},{"start":{"date-parts":[[2017,7,20]],"date-time":"2017-07-20T00:00:00Z","timestamp":1500508800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions"}],"content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd004756.pub4","type":"journal-article","created":{"date-parts":[[2017,7,21]],"date-time":"2017-07-21T11:41:22Z","timestamp":1500637282000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Polyclonal and monoclonal antibodies for treating acute rejection episodes in kidney transplant recipients"],"prefix":"10.1002","volume":"2017","author":[{"given":"Angela C","family":"Webster","sequence":"first","affiliation":[{"name":"The University of Sydney; Sydney School of Public Health; Edward Ford Building A27 Sydney NSW Australia 2006"},{"name":"The University of Sydney at Westmead; Centre for Transplant and Renal Research, Westmead Millennium Institute; Westmead NSW Australia 2145"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunny","family":"Wu","sequence":"additional","affiliation":[{"name":"The Children's Hospital at Westmead; Centre for Kidney Research; Corner Hawkesbury and Darcy Roads Westmead NSW Australia 2145"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krishna","family":"Tallapragada","sequence":"additional","affiliation":[{"name":"The Children's Hospital at Westmead; Centre for Kidney Research; Corner Hawkesbury and Darcy Roads Westmead NSW Australia 2145"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min Young","family":"Park","sequence":"additional","affiliation":[{"name":"The Children's Hospital at Westmead; Centre for Kidney Research; Corner Hawkesbury and Darcy Roads Westmead NSW Australia 2145"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremy R","family":"Chapman","sequence":"additional","affiliation":[{"name":"Westmead Millennium Institute, The University of Sydney at Westmead; Centre for Transplant and Renal Research; Darcy Rd Westmead NSW Australia 2145"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sue J","family":"Carr","sequence":"additional","affiliation":[{"name":"University Hospitals of Leicester; Renal Department; Gwendolen Rd Leicester UK LE5 4PW"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2017,7,20]]},"reference":[{"issue":"1","key":"10.1002\/14651858.CD004756.pub4-BIB0001|cit1","first-page":"273","article-title":"Randomized prospective study comparing OKT3 and antithymocyte globulins for treatment of the first acute cellular rejection of kidney allografts","volume":"26","author":"Alamartine","year":"1994","journal-title":"Transplantation Proceedings"},{"issue":"2","key":"10.1002\/14651858.CD004756.pub4-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/S0041-1345(00)00838-1","article-title":"A prospective randomized study comparing poly-ATG to mono-OKT3 clonal antibodies for the first rejection therapy after kidney transplantation: long-term results","volume":"32","author":"Baldi","year":"2000","journal-title":"Transplantation Proceedings"},{"issue":"6","key":"10.1002\/14651858.CD004756.pub4-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1111\/j.0954-6820.1975.tb19580.x","article-title":"A controlled clinical trial of treatment with ALG in established rejection of renal allografts","volume":"198","author":"Birkeland","year":"1975","journal-title":"Acta Medica Scandinavica"},{"issue":"5 Suppl","key":"10.1002\/14651858.CD004756.pub4-BIB0004|cit4","first-page":"82","article-title":"The use of antilymphocyte globulin in renal allograft rejection. A controlled study","volume":"52","author":"Birkeland","year":"1976","journal-title":"Postgraduate Medical Journal"},{"issue":"1 Pt 2","key":"10.1002\/14651858.CD004756.pub4-BIB0005|cit5","first-page":"1747","article-title":"Single center randomized trial using ATG v OKT3 treatment in steroid resistant rejection crises after kidney transplantation","volume":"21","author":"Blumke","year":"1989","journal-title":"Transplantation Proceedings"},{"issue":"1 Pt 3","key":"10.1002\/14651858.CD004756.pub4-BIB0006|cit6","first-page":"1886","article-title":"Treatment of acute rejection crisis by antilymphocyte globulins: a randomized prospective study in pediatric kidney transplantation","volume":"19","author":"Broyer","year":"1987","journal-title":"Transplantation Proceedings"},{"key":"10.1002\/14651858.CD004756.pub4-BIB0007|cit7","unstructured":"Campistol JM Oppenheimer F Vilardell J Ricart MJ Andreu J Randomized trial between OK-T3 monoclonal antibody and antilymphocyte globulin (ALG) for acute vascular graft rejection (AVGR) [abstract] 11th International Congress of Nephrology; 1990 Jul 15-20; Tokyo, Japan 1990 514A"},{"issue":"7","key":"10.1002\/14651858.CD004756.pub4-BIB0008|cit8","first-page":"785","article-title":"A randomized prospective comparison of ALG with OKT3 for treatment of renal vascular rejection [abstract]","volume":"7","author":"Poch","year":"1992","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"Program & Abstr","key":"10.1002\/14651858.CD004756.pub4-BIB0009|cit9","first-page":"677","article-title":"Preliminary results from a randomized and prospective study about immunoglobulin (IVIg) high doses vs. MoAb in the rescue of steroid resistant rejections [abstract]","volume":"8","author":"Casadei","year":"1997","journal-title":"Journal of the American Society of Nephrology"},{"issue":"5","key":"10.1002\/14651858.CD004756.pub4-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"2164","DOI":"10.1016\/S0041-1345(98)00575-2","article-title":"Preliminary results from a randomized and prospective study of high-dose immunoglobulin versus monoclonal antibody in the rescue of steroid-resistant rejections","volume":"30","author":"Casadei","year":"1998","journal-title":"Transplantation Proceedings"},{"issue":"1","key":"10.1002\/14651858.CD004756.pub4-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1097\/00007890-200101150-00009","article-title":"A randomized and prospective study comparing treatment with high-dose intravenous immunoglobulin with monoclonal antibodies for rescue of kidney grafts with steroid-resistant rejection","volume":"71","author":"Casadei","year":"2001","journal-title":"Transplantation"},{"issue":"1 Pt 1","key":"10.1002\/14651858.CD004756.pub4-BIB0012|cit12","first-page":"482","article-title":"Reversal of acute renal allograft rejection with adjunctive AG therapy","volume":"13","author":"Filo","year":"1981","journal-title":"Transplantation Proceedings"},{"issue":"6","key":"10.1002\/14651858.CD004756.pub4-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1097\/00007890-198012000-00012","article-title":"Therapy of acute cadaveric renal allograft rejection with adjunctive antithymocyte globulin","volume":"30","author":"Filo","year":"1980","journal-title":"Transplantation"},{"key":"10.1002\/14651858.CD004756.pub4-BIB0014|cit14","unstructured":"First MR US Multicenter Thymoglobulin Study Group Thymoglobulin successfully prevents recurrent rejection [abstract] 16th Annual Meeting. American Society of Transplant Physicians (ASTP); 1997 May 10-14; Chicago (ILL) 1997 259"},{"issue":"1","key":"10.1002\/14651858.CD004756.pub4-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1097\/00007890-199807150-00005","article-title":"Results of the double-blind, randomized, multicenter, phase III clinical trial of Thymoglobulin versus ATGAM in the treatment of acute graft rejection episodes after renal transplantation","volume":"66","author":"Gaber","year":"1998","journal-title":"Transplantation"},{"key":"10.1002\/14651858.CD004756.pub4-BIB0016|cit16","unstructured":"Gaber AO US Multicenter Thymoglobulin Study Group The 1996 double blinded randomized multicenter phase iii clinical trial of thymoglobulin versus ATGAM in the treatment of acute graft rejection following renal transplantation [abstract] 16th Annual Meeting. American Society of Transplant Physicians (ASTP); 1997 May 10-14; Chicago (ILL) 1997 261"},{"issue":"6","key":"10.1002\/14651858.CD004756.pub4-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"2415","DOI":"10.1046\/j.1523-1755.1999.00494.x","article-title":"Correlation of histology to clinical rejection reversal: a thymoglobulin multicenter trial report","volume":"55","author":"Gaber","year":"1999","journal-title":"Kidney International"},{"key":"10.1002\/14651858.CD004756.pub4-BIB0018|cit18","unstructured":"Gaber LW US Multicenter Thymoglobulin Study Group Correlation of post treatment renal allograft biopsies to rejection reversal [abstract] 16th Annual Meeting. American Society of Transplant Physicians (ASTP); 1997 May 10-14; Chicago (ILL) 1997 238"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD004756.pub4-BIB0019|cit19","first-page":"S324","article-title":"A multicenter trial of thymoglobulin vs ATGAM as therapy for acute renal allograft rejection (AR) [abstract no: P1002]","volume":"3","author":"Gaston","year":"1997","journal-title":"Nephrology"},{"issue":"Program & Abstr","key":"10.1002\/14651858.CD004756.pub4-BIB0020|cit20","first-page":"679A","article-title":"A multivarate logistic regression analysis of the U.S. multicenter, randomized trial of thymoglobulin (THYMO) versus ATGAM for treatment of acute renal allograft rejection [abstract]","volume":"9","author":"Irish","year":"1998","journal-title":"Journal of the American Society of Nephrology"},{"key":"10.1002\/14651858.CD004756.pub4-BIB0021|cit21","unstructured":"Regan JF Campbell K Smith L Le H Schroeder T Womble D Anti-thymoglobulin IgI and anti-ATGAM IgG in renal transplant patients undergoing treatment for acute rejection [abstract] 16th Annual Meeting. American Society of Transplant Physicians (ASTP); 1997 May 10-14; Chicago (ILL) 1997 259"},{"issue":"2","key":"10.1002\/14651858.CD004756.pub4-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/S0966-3274(99)80028-8","article-title":"Sensitization following Thymoglobulin and ATGAM rejection therapy as determined with a rapid enzyme-linked immunosorbent assay. US Thymoglobulin Multi-Center Study Group","volume":"7","author":"Regan","year":"1999","journal-title":"Transplant Immunology"},{"issue":"3","key":"10.1002\/14651858.CD004756.pub4-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"287","DOI":"10.2165\/00019053-200017030-00006","article-title":"Economics of the antithymocyte globulins Thymoglobulin and ATGAM in the treatment of acute renal transplant rejection","volume":"17","author":"Schnitzler","year":"2000","journal-title":"Pharmacoeconomics"},{"issue":"3B Suppl","key":"10.1002\/14651858.CD004756.pub4-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"7S","DOI":"10.1016\/S0041-1345(99)00093-7","article-title":"Costs savings associated with thymoglobulin for treatment of acute renal transplant rejection in patient subsets","volume":"31","author":"Schnitzler","year":"1999","journal-title":"Transplantation Proceedings"},{"issue":"1-2","key":"10.1002\/14651858.CD004756.pub4-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/S0041-1345(98)01530-9","article-title":"High risk kidney transplant rejection treatment: cost savings from thymoglobulin","volume":"31","author":"Schnitzler","year":"1999","journal-title":"Transplantation Proceedings"},{"issue":"7","key":"10.1002\/14651858.CD004756.pub4-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"S151","DOI":"10.1097\/00007890-199904150-00604","article-title":"Economics of thymoglobulin versus ATGAM for induction immunosuppression in renal transplantation [abstract no: 578]","volume":"67","author":"Schnitzler","year":"1999","journal-title":"Transplantation"},{"issue":"3B Suppl","key":"10.1002\/14651858.CD004756.pub4-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"1S","DOI":"10.1016\/S0041-1345(99)00092-5","article-title":"The US multicenter double-blind, randomized, phase III trial of thymoglobulin versus ATGAM in the treatment of acute graft rejection episodes following renal transplantation: rationale for study design","volume":"31","author":"Schroeder","year":"1999","journal-title":"Transplantation Proceedings"},{"issue":"7A","key":"10.1002\/14651858.CD004756.pub4-BIB0028|cit28","doi-asserted-by":"crossref","first-page":"21S","DOI":"10.1016\/S0041-1345(97)80005-X","article-title":"Thymoglobulin reverses acute renal allograft rejection better than ATGAM--a double-blinded randomized clinical trial","volume":"29","author":"Tesi","year":"1997","journal-title":"Transplantation Proceedings"},{"issue":"Program & Abstr","key":"10.1002\/14651858.CD004756.pub4-BIB0029|cit29","first-page":"703","article-title":"Thymoglobulin (THYMO) may be more efficacious than ATGAM for reducing recurrent acute renal allograft rejection: results of the US multicenter, double-blinded, comparative trial [abstract]","volume":"9","author":"Woodle","year":"1998","journal-title":"Journal of the American Society of Nephrology"},{"issue":"12","key":"10.1002\/14651858.CD004756.pub4-BIB0030|cit30","doi-asserted-by":"crossref","first-page":"S191","DOI":"10.1097\/00007890-199806270-00772","article-title":"12 month intent to treat analysis of the double blind, randomized multicenter thymoglobulin vs ATGAM trial for the treatment of acute rejection following renal transplantation [abstract]","volume":"65","author":"Woodle","year":"1998","journal-title":"Transplantation"},{"issue":"1","key":"10.1002\/14651858.CD004756.pub4-BIB0031|cit31","first-page":"617","article-title":"A comparative study of steroids and heterologous antiserum in the treatment of renal allograft rejection","volume":"15","author":"Glass","year":"1983","journal-title":"Transplantation Proceedings"},{"issue":"6","key":"10.1002\/14651858.CD004756.pub4-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1056\/NEJM198508083130601","article-title":"A randomized clinical trial of OKT3 monoclonal antibody for acute rejection of cadaveric renal transplants. Ortho Multicenter Transplant Study Group","volume":"313","year":"1985","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD004756.pub4-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1159\/000184430","article-title":"OKT3: First-dose safety and success","volume":"46 Suppl 1","author":"Cosimi","year":"1987","journal-title":"Nephron"},{"key":"10.1002\/14651858.CD004756.pub4-BIB0034|cit34","first-page":"239","article-title":"OKT3 monoclonal antibody reversal of acute renal allograft rejection unresponsive to conventional immunosuppressive treatments","volume":"224","author":"Goldstein","year":"1986","journal-title":"Progress in Clinical & Biological Research"},{"issue":"5","key":"10.1002\/14651858.CD004756.pub4-BIB0035|cit35","first-page":"2273","article-title":"Preliminary results of a prospectively randomized trial of ALG vs OKT3 for steroid-resistant rejection after renal transplantation in the early postoperative period","volume":"22","author":"Hesse","year":"1990","journal-title":"Transplantation Proceedings"},{"key":"10.1002\/14651858.CD004756.pub4-BIB0036|cit36","doi-asserted-by":"crossref","first-page":"S440","DOI":"10.1111\/tri.1992.5.s1.440","article-title":"The risk of infection following OKT3 and antilymphocyte globulin treatment for renal transplant rejection: results of a single center prospectively randomized trial","volume":"5 Suppl 1","author":"Hesse","year":"1992","journal-title":"Transplant International"},{"issue":"6","key":"10.1002\/14651858.CD004756.pub4-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"2201","DOI":"10.1016\/S0041-1345(02)03200-1","article-title":"ALG versus OKT3 for treatment of steroid-resistant rejection in renal transplantation: ten-year follow-up results of a randomized trial","volume":"34","author":"Stippel","year":"2002","journal-title":"Transplantation Proceedings"},{"issue":"8","key":"10.1002\/14651858.CD004756.pub4-BIB0038|cit38","first-page":"1675","article-title":"Methylprednisolone versus ATG as initial treatment for acute rejections after renal transplantation [abstract]","volume":"11","author":"Hilbrands","year":"1996","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"1","key":"10.1002\/14651858.CD004756.pub4-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1097\/00007890-198201000-00003","article-title":"Treatment of acute rejection of cadaveric renal allografts with rabbit antithymocyte globulin","volume":"33","author":"Hoitsma","year":"1982","journal-title":"Transplantation"},{"issue":"3","key":"10.1002\/14651858.CD004756.pub4-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1097\/00007890-198503000-00013","article-title":"Improved patient and graft survival after treatment of acute rejections of cadaveric renal allografts with rabbit antithymocyte globulin","volume":"39","author":"Hoitsma","year":"1985","journal-title":"Transplantation"},{"issue":"41","key":"10.1002\/14651858.CD004756.pub4-BIB0041|cit41","first-page":"2093","article-title":"Use of cyclosporin A after antilymphocyte serum in renal transplantation","volume":"14","author":"Hourmant","year":"1985","journal-title":"Presse Medicale"},{"issue":"1","key":"10.1002\/14651858.CD004756.pub4-BIB0042|cit42","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/0168-8510(88)90119-4","article-title":"Economic analysis of an immunosuppressive strategy in renal transplantation","volume":"9","author":"Schneider","year":"1988","journal-title":"Health Policy"},{"issue":"1 Pt 1","key":"10.1002\/14651858.CD004756.pub4-BIB0043|cit43","first-page":"473","article-title":"The use of antilymphoblast globulin in the treatment of renal allograft rejection","volume":"13","author":"Howard","year":"1981","journal-title":"Transplantation Proceedings"},{"issue":"6","key":"10.1002\/14651858.CD004756.pub4-BIB0044|cit44","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1097\/00007890-197712000-00004","article-title":"The use of antilymphoblast globulin in the treatment of renal allograft rejection: a double-blind, randomized study","volume":"24","author":"Howard","year":"1977","journal-title":"Transplantation"},{"issue":"1 Pt 2","key":"10.1002\/14651858.CD004756.pub4-BIB0045|cit45","first-page":"1734","article-title":"Multicenter comparison of rejection reversal: rabbit anti-human lymphocyte serum (ATS) versus horse anti-human lymphocyte globulin (ATGAM)","volume":"21","author":"Johnson","year":"1989","journal-title":"Transplantation Proceedings"},{"issue":"1","key":"10.1002\/14651858.CD004756.pub4-BIB0046|cit46","first-page":"460","article-title":"The effectiveness of rabbit anti-thymocyte serum (ATS) in the reversal of acute allograft rejection - a multicenter study [abstract]","volume":"31","author":"Johnson","year":"1987","journal-title":"Kidney International"},{"issue":"3","key":"10.1002\/14651858.CD004756.pub4-BIB0047|cit47","first-page":"231","article-title":"A randomized prospective study comparing low-dose OKT3 to low-dose ATG for the treatment of acute steroid-resistant rejection episodes in kidney transplant recipients","volume":"11","author":"Mariat","year":"1998","journal-title":"Transplant International"},{"issue":"6","key":"10.1002\/14651858.CD004756.pub4-BIB0048|cit48","first-page":"276","article-title":"Randomized prospective study comparing low-dose OKT3 to low-dose antithymocyte globulins for treatment of the first acute rejection of kidney allografts [abstract]","volume":"11","author":"Mariat","year":"1996","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"1","key":"10.1002\/14651858.CD004756.pub4-BIB0049|cit49","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1097\/00007890-199607150-00008","article-title":"Half dose of OKT3 is efficient in treatment of steroid-resistant renal allograft rejection","volume":"62","author":"Midtvedt","year":"1996","journal-title":"Transplantation"},{"issue":"3","key":"10.1002\/14651858.CD004756.pub4-BIB0050|cit50","first-page":"1106","article-title":"OKT3, doses of 2.5mg versus 5mg in steroid resistant renal allograft rejections [abstract]","volume":"6","author":"Midtvedt","year":"1995","journal-title":"Journal of the American Society of Nephrology"},{"key":"10.1002\/14651858.CD004756.pub4-BIB0051|cit51","doi-asserted-by":"crossref","unstructured":"Fauchald P Midtvedt K Lien B Hartmann A Albrechtsen D Bjerkely BL Randomized trial of T-cell monitored administration of ATG vs OKT3 in steroid resistant kidney graft rejection [abstract] XIXth International Congress of the Transplantation Society; 2002 Aug 25-30; Miami (FL) 2002","DOI":"10.1034\/j.1399-0012.2003.02105.x"},{"issue":"1","key":"10.1002\/14651858.CD004756.pub4-BIB0052|cit52","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1034\/j.1399-0012.2003.02105.x","article-title":"Individualized T cell monitored administration of ATG versus OKT3 in steroid-resistant kidney graft rejection","volume":"17","author":"Midtvedt","year":"2003","journal-title":"Clinical Transplantation"},{"issue":"3","key":"10.1002\/14651858.CD004756.pub4-BIB0053|cit53","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1097\/00007890-199303000-00010","article-title":"15-Deoxyspergualin \"rescue therapy\" for methylprednisolone-resistant rejection of renal transplants as compared with anti-T cell monoclonal antibody (OKT3)","volume":"55","author":"Okubo","year":"1993","journal-title":"Transplantation"},{"issue":"6","key":"10.1002\/14651858.CD004756.pub4-BIB0054|cit54","first-page":"3434","article-title":"Three-day or ten-day ATG treatment for steroid-resistant rejection in kidney transplanted patients","volume":"27","author":"Olausson","year":"1995","journal-title":"Transplantation Proceedings"},{"key":"10.1002\/14651858.CD004756.pub4-BIB0055|cit55","doi-asserted-by":"crossref","first-page":"S38","DOI":"10.1111\/j.1432-2277.1996.tb01656.x","article-title":"Steroid-resistant rejection in kidney-transplanted patients: is ATG treatment for three or ten days preferable?","volume":"9 Suppl 1","author":"Olausson","year":"1996","journal-title":"Transplant International"},{"issue":"2","key":"10.1002\/14651858.CD004756.pub4-BIB0056|cit56","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1097\/TP.0000000000000958","article-title":"One year results of the effects of rituximab on acute antibody-mediated rejection in renal transplantation: RITUX ERAH, a multicenter double-blind randomized placebo-controlled trial","volume":"100","author":"Sautenet","year":"2016","journal-title":"Transplantation"},{"issue":"Suppl S5","key":"10.1002\/14651858.CD004756.pub4-BIB0057|cit57","first-page":"112","article-title":"One year results of the effects of rituximab on acute humoral rejection in renal transplantation: RITUX ERAH, a multicenter randomized placebo controlled trial [abstract no: 266]","volume":"13","author":"Sautenet","year":"2013","journal-title":"American Journal of Transplantation"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD004756.pub4-BIB0058|cit58","first-page":"110","article-title":"RITUX-ERAH: Multicenter randomized trial of rituximab on acute humoral rejection in transplantation [abstract no:O218]","volume":"26","author":"Sautenet","year":"2013","journal-title":"Transplant International"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD004756.pub4-BIB0059|cit59","first-page":"22","article-title":"RITUX-ERAH: multicenter randomized trial of rituximab on acute antibody mediated rejection in transplantation [abstract no: O90]","volume":"26","author":"Sautenet","year":"2013","journal-title":"Transplant International"},{"issue":"6","key":"10.1002\/14651858.CD004756.pub4-BIB0060|cit60","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1097\/00007890-197912000-00005","article-title":"Use of antithymocyte globulin for reversal of acute allograft rejection","volume":"28","author":"Shield","year":"1979","journal-title":"Transplantation"},{"issue":"1","key":"10.1002\/14651858.CD004756.pub4-BIB0061|cit61","first-page":"295","article-title":"Reversal of acute cadaveric renal allograft rejection with adjunctive ATG treatment [abstract]","volume":"23","author":"Simonian","year":"1983","journal-title":"Kidney International"},{"issue":"2","key":"10.1002\/14651858.CD004756.pub4-BIB0062|cit62","first-page":"84","article-title":"Cardiovascular effects of the rejection therapy with antibodies against lymphocytes","volume":"23","author":"Barenbrock","year":"1994","journal-title":"Nieren-und Hochdruckkrankheiten"},{"issue":"6","key":"10.1002\/14651858.CD004756.pub4-BIB0063|cit63","first-page":"2594","article-title":"Cardiovascular effects of ATG and OKT3 in renal allograft recipients","volume":"24","author":"Spieker","year":"1992","journal-title":"Transplantation Proceedings"},{"issue":"5","key":"10.1002\/14651858.CD004756.pub4-BIB0064|cit64","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1097\/00007890-198305000-00005","article-title":"Low-dose maintenance prednisone and antilymphoblast globulin for the treatment of acute rejection. A steroid-sparing approach to immunosuppressive therapy","volume":"35","author":"Streem","year":"1983","journal-title":"Transplantation"},{"key":"10.1002\/14651858.CD004756.pub4-BIB0065|cit65","doi-asserted-by":"crossref","first-page":"S86","DOI":"10.1111\/j.1432-2277.1998.tb01203.x","article-title":"Aggressive treatment of the first acute rejection episode using first-line anti-lymphocytic preparation reduces further acute rejection episodes after human kidney transplantation","volume":"11 Suppl 1","author":"Theodorakis","year":"1998","journal-title":"Transplant International"},{"issue":"4","key":"10.1002\/14651858.CD004756.pub4-BIB0066|cit66","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1097\/00007890-198510000-00023","article-title":"A prospective randomized comparison of antilymphoblast globulin versus antithymocyte globulin for cadaver kidney transplantation","volume":"40","author":"Toledo-Pereyra","year":"1985","journal-title":"Transplantation"},{"issue":"2","key":"10.1002\/14651858.CD004756.pub4-BIB0067|cit67","first-page":"388","article-title":"Comparison of ALG and ATG for renal transplantation [abstract]","volume":"28","author":"Toledo-Pereyra","year":"1985","journal-title":"Kidney International"},{"issue":"1 Pt 1","key":"10.1002\/14651858.CD004756.pub4-BIB0068|cit68","first-page":"543","article-title":"Comparison of T10Bg.1A-31 and OKT3 in treating acute renal allograft rejection","volume":"25","author":"Lucas","year":"1993","journal-title":"Transplantation Proceedings"},{"issue":"3","key":"10.1002\/14651858.CD004756.pub4-BIB0069|cit69","first-page":"886","article-title":"Treatment of acute rejection in renal allografts with t10b9.1a-31 or OKT3 monoclonal antibody [abstract]","volume":"3","author":"Waid","year":"1992","journal-title":"Journal of the American Society of Nephrology"},{"issue":"1","key":"10.1002\/14651858.CD004756.pub4-BIB0070|cit70","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1097\/00007890-199201000-00015","article-title":"Treatment of acute cellular rejection with T10B9.1A-31 or OKT3 in renal allograft recipients","volume":"53","author":"Waid","year":"1992","journal-title":"Transplantation"},{"issue":"2","key":"10.1002\/14651858.CD004756.pub4-BIB0071|cit71","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1097\/00007890-199707270-00017","article-title":"Treatment of renal allograft rejection with T10B9.1A31 or OKT3: final analysis of a phase II clinical trial","volume":"64","author":"Waid","year":"1997","journal-title":"Transplantation"},{"issue":"3","key":"10.1002\/14651858.CD004756.pub4-BIB0072|cit72","first-page":"1042","article-title":"Improved graft and patient survival with t10b9 1-a or OKT3 monoclonal antibody for treatment for primary rejection [abstract]","volume":"5","author":"Waid","year":"1994","journal-title":"Journal of the American Society of Nephrology"},{"issue":"3","key":"10.1002\/14651858.CD004756.pub4-BIB0073|cit73","first-page":"1042","article-title":"T10B9.1A-31 effectively reverses renal allograft rejection crises with fewer side effects, less cytokine release and no severe infections [abstract]","volume":"5","author":"Waid","year":"1994","journal-title":"Journal of the American Society of Nephrology"},{"issue":"1 Pt 2","key":"10.1002\/14651858.CD004756.pub4-BIB0074|cit74","first-page":"1062","article-title":"Treatment of acute rejection with anti-T-cell antigen receptor complex alpha beta (T10B9.1A-31) or anti-CD3 (OKT3) monoclonal antibody: results of a prospective randomized double-blind trial","volume":"23","author":"Waid","year":"1991","journal-title":"Transplantation Proceedings"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD004756.pub4-BIB0075|cit75","first-page":"287","article-title":"Randomized trial of Rituximab vs standard of care for B cell dense acute renal transplant rejection [abstract no: 538]","volume":"7","author":"Sarwal","year":"2007","journal-title":"American Journal of Transplantation"},{"issue":"12","key":"10.1002\/14651858.CD004756.pub4-BIB0076|cit76","doi-asserted-by":"crossref","first-page":"2607","DOI":"10.1111\/j.1600-6143.2008.02411.x","article-title":"A randomized, prospective trial of rituximab for acute rejection in pediatric renal transplantation","volume":"8","author":"Zarkhin","year":"2008","journal-title":"American Journal of Transplantation"},{"issue":"3","key":"10.1002\/14651858.CD004756.pub4-BIB0077|cit77","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1111\/ajt.14001","article-title":"Eculizumab therapy for chronic antibody-mediated injury in kidney transplant recipients: a pilot, randomized-controlled trial","volume":"17","author":"Kulkarni","year":"2016","journal-title":"American Journal of Transplantation"},{"key":"10.1002\/14651858.CD004756.pub4-BIB0078|cit78","first-page":"199","article-title":"Rationale and design of the RIACT-study: a multi-center placebo controlled double blind study to test the efficacy of rItuximab in acute cellular tubulointerstitial rejection with B-cell infiltrates in renal transplant patients: study protocol for a randomized controlled trial","volume":"13","author":"Schiffer","year":"2012","journal-title":"Trials [Electronic Resource]"},{"key":"10.1002\/14651858.CD004756.pub4-BIB0079|cit79","unstructured":"Excell L Chadban S McDonald S ANZDATA 27th Annual Report. Chapter 8: Transplantation www.anzdata.org.au\/anzdata\/AnzdataReport\/27thReport\/files\/Ch08Transplantation.pdf"},{"key":"10.1002\/14651858.CD004756.pub4-BIB0080|cit80","unstructured":"Clayton P Campbell S Chadban S McDonald S Hurst K ANZDATA 35th Annual Report. Chapter 8: transplantation www.anzdata.org.au\/anzdata\/AnzdataReport\/35thReport\/2012c08_transplants_v1.5.pdf"},{"issue":"2","key":"10.1002\/14651858.CD004756.pub4-BIB0081|cit81","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1111\/j.1432-2277.2011.01309.x","article-title":"Prevention and treatment of alloantibody-mediated kidney transplant rejection","volume":"24","author":"Bartel","year":"2011","journal-title":"Transplant International"},{"issue":"2","key":"10.1002\/14651858.CD004756.pub4-BIB0082|cit82","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1016\/j.transproceed.2004.12.019","article-title":"Reversal of acute cellular rejection after renal transplantation with Campath-1H","volume":"37","author":"Basu","year":"2005","journal-title":"Transplantation Proceedings"},{"issue":"7494","key":"10.1002\/14651858.CD004756.pub4-BIB0083|cit83","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1136\/bmj.38356.424606.8F","article-title":"Identifying outcome reporting bias in randomised trials on PubMed: review of publications and survey of authors","volume":"330","author":"Chan","year":"2005","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD004756.pub4-BIB0084|cit84","unstructured":"Chon WJ Brennan DC Acute renal allograft rejection: treatment www.uptodate.com\/contents\/acute-renal-allograft-rejection-treatment"},{"issue":"10","key":"10.1002\/14651858.CD004756.pub4-BIB0085|cit85","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1038\/nri1702","article-title":"Antibody-mediated organ-allograft rejection","volume":"5","author":"Colvin","year":"2005","journal-title":"Nature Reviews. Immunology"},{"issue":"5","key":"10.1002\/14651858.CD004756.pub4-BIB0086|cit86","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1016\/j.transproceed.2005.03.042","article-title":"Campath-1H as rescue therapy for the treatment of acute rejection in kidney transplant patients","volume":"37","author":"Csapo","year":"2005","journal-title":"Transplantation Proceedings"},{"issue":"7406","key":"10.1002\/14651858.CD004756.pub4-BIB0087|cit87","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1136\/bmj.327.7406.65","article-title":"Balancing benefits and harms in health care","volume":"327","author":"Cuervo","year":"2003","journal-title":"BMJ"},{"issue":"9158","key":"10.1002\/14651858.CD004756.pub4-BIB0088|cit88","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1016\/S0140-6736(98)07493-5","article-title":"Immunosuppressive strategies in transplantation","volume":"353","author":"Denton","year":"1999","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD004756.pub4-BIB0089|cit89","doi-asserted-by":"publisher","DOI":"10.5772\/54735","article-title":"Chapter 5: Detection of antibody-mediated rejection in kidney transplantation and the management of highly sensitised kidney transplant recipients","volume-title":"Current Issues and Future Direction in Kidney Transplantation","author":"Dheda","year":"2013"},{"key":"10.1002\/14651858.CD004756.pub4-BIB0090|cit90","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1002\/9780470693926.ch3","article-title":"Problems and limitations in conducting systematic reviews","volume-title":"Systematic Reviews in Health Care","author":"Egger","year":"2001"},{"issue":"7650","key":"10.1002\/14651858.CD004756.pub4-BIB0091|cit91","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"issue":"5","key":"10.1002\/14651858.CD004756.pub4-BIB0092|cit92","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1111\/ajt.13661","article-title":"The revised (2013) Banff classification for antibody-mediated rejection of renal allografts: update, difficulties, and future considerations","volume":"16","author":"Haas","year":"2016","journal-title":"American Journal of Transplantation"},{"issue":"26","key":"10.1002\/14651858.CD004756.pub4-BIB0093|cit93","doi-asserted-by":"crossref","first-page":"2715","DOI":"10.1056\/NEJMra033540","article-title":"Immunosuppressive drugs for kidney transplantation. [Review] [124 refs][Erratum appears in N Engl J Med. 2005 Mar 10;352(10):1056]","volume":"351","author":"Halloran","year":"2004","journal-title":"New England Journal of Medicine"},{"issue":"4","key":"10.1002\/14651858.CD004756.pub4-BIB0094|cit94","doi-asserted-by":"crossref","first-page":"68","DOI":"10.5500\/wjt.v3.i4.68","article-title":"Novel immunosuppressive agents in kidney transplantation","volume":"3","author":"Hardinger","year":"2013","journal-title":"World Journal of Transplantation"},{"issue":"7414","key":"10.1002\/14651858.CD004756.pub4-BIB0095|cit95","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD004756.pub4-BIB0096|cit96","unstructured":"Higgins JP Green S (editors) Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011 Available from www.cochrane-handbook.org"},{"issue":"7211","key":"10.1002\/14651858.CD004756.pub4-BIB0097|cit97","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1136\/bmj.319.7211.670","article-title":"What is meant by intention to treat analysis? Survey of published randomised controlled trials","volume":"319","author":"Hollis","year":"1999","journal-title":"BMJ"},{"issue":"1","key":"10.1002\/14651858.CD004756.pub4-BIB0098|cit98","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s00467-008-1020-x","article-title":"Mechanism of cellular rejection in transplantation","volume":"25","author":"Ingulli","year":"2010","journal-title":"Pediatric Nephrology"},{"issue":"1","key":"10.1002\/14651858.CD004756.pub4-BIB0099|cit99","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1586\/eci.09.64","article-title":"Role of T cells in graft rejection and transplantation tolerance","volume":"6","author":"Issa","year":"2010","journal-title":"Expert Review of Clinical Immunology"},{"issue":"1","key":"10.1002\/14651858.CD004756.pub4-BIB0100|cit100","first-page":"e24439","article-title":"The impact of acute rejection in kidney transplantation on long-term allograft and patient outcome","volume":"7","author":"Jalalzadeh","year":"2015","journal-title":"Nephrourology Monthly"},{"issue":"3","key":"10.1002\/14651858.CD004756.pub4-BIB0101|cit101","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1586\/eci.11.10","article-title":"Regulation of immunity and inflammation by intravenous immunoglobulin: relevance to solid organ transplantation","volume":"7","author":"Jordan","year":"2011","journal-title":"Expert Review of Clinical Immunology"},{"issue":"4","key":"10.1002\/14651858.CD004756.pub4-BIB0102|cit102","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1034\/j.1399-0012.2001.150401.x","article-title":"The impact of late acute rejection after cadaveric kidney transplantation","volume":"15","author":"Joseph","year":"2001","journal-title":"Clinical Transplantation"},{"issue":"3","key":"10.1002\/14651858.CD004756.pub4-BIB0103|cit103","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.krcp.2015.06.003","article-title":"The impact of early and late acute rejection on graft survival in renal transplantation","volume":"34","author":"Koo","year":"2015","journal-title":"Kidney Research & Clinical Practice"},{"issue":"1","key":"10.1002\/14651858.CD004756.pub4-BIB0104|cit104","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/1472-6904-1-3","article-title":"Reporting of adverse drug reactions in randomised controlled trials - a systematic survey","volume":"1","author":"Loke","year":"2001","journal-title":"BMC Clinical Pharmacology"},{"issue":"5","key":"10.1002\/14651858.CD004756.pub4-BIB0105|cit105","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1111\/j.1432-2277.2000.tb01008.x","article-title":"Completely reversed acute rejection is not a significant risk factor for the development of chronic rejection in renal allograft recipients","volume":"13","author":"Madden","year":"2000","journal-title":"Transplant International"},{"issue":"11","key":"10.1002\/14651858.CD004756.pub4-BIB0106|cit106","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD010699.pub2","article-title":"Belatacept for kidney transplant recipients","author":"Masson","year":"2014","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD004756.pub4-BIB0107|cit107","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/ajt.12579","article-title":"OPTN\/SRTR 2012 Annual Data Report: kidney","volume":"14 Suppl 1","author":"Matas","year":"2014","journal-title":"American Journal of Transplantation"},{"issue":"2","key":"10.1002\/14651858.CD004756.pub4-BIB0108|cit108","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1111\/j.1600-6143.2006.01635.x","article-title":"Infiltrates in protocol biopsies from renal allografts","volume":"7","author":"Mengel","year":"2007","journal-title":"American Journal of Transplantation"},{"issue":"15","key":"10.1002\/14651858.CD004756.pub4-BIB0109|cit109","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1056\/NEJMra0902927","article-title":"Rejection of the kidney allograft","volume":"363","author":"Nankivell","year":"2010","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD004756.pub4-BIB0110|cit110","unstructured":"Immunosuppressive therapy for renal transplantation in adults. London (UK): National Institute for Clinical Excellence (NICE); September 2004. Technology appraisal [TA85] www.nice.org.uk\/guidance\/ta85"},{"issue":"1-2","key":"10.1002\/14651858.CD004756.pub4-BIB0111|cit111","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/S0041-1345(96)00013-9","article-title":"Critical evaluation of the association of acute with chronic graft rejection in kidney and heart transplant recipients. The Collaborative Transplant Study","volume":"29","author":"Opelz","year":"1997","journal-title":"Transplantation Proceedings"},{"issue":"5","key":"10.1002\/14651858.CD004756.pub4-BIB0112|cit112","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1097\/TP.0b013e3181661695","article-title":"Influence of time of rejection on long-term graft survival in renal transplantation","volume":"85","author":"Opelz","year":"2008","journal-title":"Transplantation"},{"issue":"13","key":"10.1002\/14651858.CD004756.pub4-BIB0113|cit113","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1002\/sim.4780121302","article-title":"Analysis as-randomized and the problem of non-adherence: an example from the Veterans Affairs Randomized Trial of Coronary Artery Bypass Surgery","volume":"12","author":"Peduzzi","year":"1993","journal-title":"Statistics in Medicine"},{"issue":"8","key":"10.1002\/14651858.CD004756.pub4-BIB0114|cit114","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1097\/TP.0b013e31825d1587","article-title":"The treatment of acute antibody-mediated rejection in kidney transplant recipients-a systematic review","volume":"94","author":"Roberts","year":"2012","journal-title":"Transplantation"},{"issue":"26","key":"10.1002\/14651858.CD004756.pub4-BIB0115|cit115","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1056\/NEJM197912273012602","article-title":"Controversy in counting and attributing events in clinical trials","volume":"301","author":"Sackett","year":"1979","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD004756.pub4-BIB0116|cit116","unstructured":"Sch\u00fcnemann HJ Oxman AD Higgins JP Vist GE Glasziou P Guyatt GH Chapter 11: Presenting results and 'Summary of findings' tables. In: Higgins JP, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011 Available from www.cochrane-handbook.org"},{"key":"10.1002\/14651858.CD004756.pub4-BIB0117|cit117","unstructured":"Sch\u00fcnemann HJ Oxman AD Higgins JP Deeks JJ Glasziou P Guyatt GH Chapter 12: Interpreting results and drawing conclusions. In: Higgins JP, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011 Available from www.cochrane-handbook.org"},{"issue":"2","key":"10.1002\/14651858.CD004756.pub4-BIB0118|cit118","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1038\/ki.1993.259","article-title":"International standardization of criteria for the histologic diagnosis of renal allograft rejection: the Banff working classification of kidney transplant pathology","volume":"44","author":"Solez","year":"1993","journal-title":"Kidney International"},{"issue":"4","key":"10.1002\/14651858.CD004756.pub4-BIB0119|cit119","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1111\/j.1600-6143.2008.02159.x","article-title":"Banff 07 classification of renal allograft pathology: updates and future directions","volume":"8","author":"Solez","year":"2008","journal-title":"American Journal of Transplantation"},{"issue":"11","key":"10.1002\/14651858.CD004756.pub4-BIB0120|cit120","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1681\/ASN.V8111771","article-title":"Effect of anti-lymphocyte induction therapy on renal allograft survival: a meta-analysis","volume":"8","author":"Szczech","year":"1997","journal-title":"Journal of the American Society of Nephrology"},{"issue":"10","key":"10.1002\/14651858.CD004756.pub4-BIB0121|cit121","doi-asserted-by":"crossref","first-page":"817","DOI":"10.7326\/0003-4819-128-10-199805150-00004","article-title":"The effect of antilymphocyte induction therapy on renal allograft survival. A meta-analysis of individual patient-level data. Anti-Lymphocyte Antibody Induction Therapy Study Group","volume":"128","author":"Szczech","year":"1998","journal-title":"Annals of Internal Medicine"},{"issue":"12","key":"10.1002\/14651858.CD004756.pub4-BIB0122|cit122","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1001\/jama.290.12.1624","article-title":"Practical clinical trials; increasing the value of clinical research for decision making in clinical and health policy","volume":"290","author":"Tunis","year":"2003","journal-title":"JAMA"},{"key":"10.1002\/14651858.CD004756.pub4-BIB0123|cit123","unstructured":"National Institutes of Health National Institute of Diabetes and Digestive and Kidney Diseases Bethesda MD 2014 USRDS Annual data report: Epidemiology of kidney disease in the United States Volume 2: End-stage renal disease (ESRD) in the United States. Chapter 6: Transplantation www.usrds.org\/2014\/view\/v2_06.aspx"},{"issue":"3","key":"10.1002\/14651858.CD004756.pub4-BIB0124|cit124","doi-asserted-by":"crossref","first-page":"869","DOI":"10.3390\/toxins6030869","article-title":"Monoclonal antibody therapy and renal transplantation: focus on adverse effects","volume":"6","author":"Zaza","year":"2014","journal-title":"Toxins"},{"issue":"2","key":"10.1002\/14651858.CD004756.pub4-BIB0125|cit125","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD004756.pub2","article-title":"Polyclonal and monoclonal antibodies for treating acute rejection episodes in kidney transplant recipients","author":"Webster","year":"2004","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"2","key":"10.1002\/14651858.CD004756.pub4-BIB0126|cit126","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD004756.pub3","article-title":"Polyclonal and monoclonal antibodies for treating acute rejection episodes in kidney transplant recipients","author":"Webster","year":"2006","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"7","key":"10.1002\/14651858.CD004756.pub4-BIB0127|cit127","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1097\/01.tp.0000215178.72344.9d","article-title":"Monoclonal and polyclonal antibody therapy for treating acute rejection in kidney transplant recipients: a systematic review of randomized trial data","volume":"81","author":"Webster","year":"2006","journal-title":"Transplantation"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full\/10.1002\/14651858.CD004756.pub4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,27]],"date-time":"2024-02-27T11:49:55Z","timestamp":1709034595000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD004756.pub4"}},"subtitle":[],"editor":[{"name":"Cochrane Kidney and Transplant Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2017,7,20]]},"references-count":127,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2017,7]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd004756.pub4","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,7,20]]}}}